TCGA-AC-A7VC-01A-11R-A352-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- MYC_TARGETS_V2+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- HEDGEHOG_SIGNALING+0.340
- MYOGENESIS+0.310
- APICAL_JUNCTION+0.250
- E2F_TARGETS+0.240
- MYC_TARGETS_V1+0.240
- COAGULATION+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- ESTROGEN_RESPONSE_EARLY-0.480
- PROTEIN_SECRETION-0.460
- INTERFERON_GAMMA_RESPONSE-0.420
- ESTROGEN_RESPONSE_LATE-0.380
- ANDROGEN_RESPONSE-0.310
- HEME_METABOLISM-0.290
- PEROXISOME-0.280
- ADIPOGENESIS-0.230
- PI3K_AKT_MTOR_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R99 | — | — | 0.820 |
| 2 | ERR2208898 | — | — | 0.756 |
| 3 | TCGA-AO-A12F-01A-11R-A115-07 | — | E | 0.754 |
| 4 | SRR975559 | — | — | 0.728 |
| 5 | SRR25617931 | — | E | 0.723 |
| 6 | TCGA-AC-A5XU-01A-11R-A28M-07 | — | B | 0.722 |
| 7 | TCGA-AR-A2LR-01A-12R-A18M-07 | — | E | 0.721 |
| 8 | MNG692 | — | — | 0.715 |
| 9 | TCGA-AN-A0FX-01A-11R-A034-07 | — | E | 0.714 |
| 10 | SRR2016936 | — | — | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |